Ruxolitinib for Systemic Juvenile Idiopathic Arthritis Complicated by Macrophage Activation Syndrome: Two Pediatric Cases and Literature Review - Summary - MDSpire
Advertisement
Ruxolitinib for Systemic Juvenile Idiopathic Arthritis Complicated by Macrophage Activation Syndrome: Two Pediatric Cases and Literature Review
To explore the efficacy and safety of ruxolitinib in children with systemic juvenile idiopathic arthritis complicated by macrophage activation syndrome (sJIA‑MAS), particularly in those with refractory disease.
Key Findings:
Both patients showed marked improvement in systemic hyperinflammation during ruxolitinib therapy.
Case 1: A 19-month-old boy with respiratory failure improved rapidly after starting ruxolitinib, allowing glucocorticoids to be discontinued within three months.
Case 2: A 4-year-old girl with acute respiratory distress syndrome normalized body temperature within two days of ruxolitinib initiation and discontinued glucocorticoids within six months.
Five out of seven previously reported pediatric cases achieved complete remission with ruxolitinib.
No deaths were reported among the reviewed cases, though one patient developed Epstein–Barr virus-associated hemophagocytic lymphohistiocytosis.
Interpretation:
Limitations:
Small sample size with only two cases from the center and a limited number of previously reported cases.
Retrospective nature of the review may introduce bias.
